Abstract
Transmembrane signaling through G protein–coupled receptors (GPCRs) controls a diverse array of cellular processes including metabolism, growth, motility, adhesion, neuronal signaling and blood coagulation. The numerous GPCRs and their key roles in both normal physiology and disease have made them the target for more than 50% of all prescribed drugs. GPCR agonists and antagonists act on the extracellular side of the receptors, whereas the intracellular surface has not yet been exploited for development of new therapeutic agents. Here, we demonstrate the utility of novel cell-penetrating peptides, termed 'pepducins', that act as intracellular inhibitors of signal transference from receptors to G proteins1. Attachment of a palmitate lipid to peptides based on the third intracellular loop of protease-activated receptor 1 (PAR1)2 or PAR4 (refs. 3–5) yielded potent inhibitors of thrombin-mediated aggregation of human platelets. Infusion of the anti-PAR4 pepducin into mice extended bleeding time and protected against systemic platelet activation, consistent with the phenotype of PAR4-deficient mice. We show that pepducins might be used to ascertain the physiological roles of GPCRs and rapidly determine the potential therapeutic value of blockade of a particular signaling pathway.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Covic, L., Gresser, A.L., Talavera, J., Swift, S. & Kuliopulos, A. Activation and inhibition of G protein–coupled receptors by cell-penetrating, membrane-tethered peptides. Proc. Natl. Acad. Sci. USA 99, 643–648 (2002).
Vu, T.-K.H., Hung, D.T., Wheaton, V.I. & Coughlin, S.R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor action. Cell 64, 1057–1068 (1991).
Xu, W.-F. et al. Cloning and characterization of human protease-activated receptor 4. Proc. Natl. Acad. Sci. USA 95, 6642–6646 (1998).
Covic, L., Gresser, A.L. & Kuliopulos, A. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry 39, 5458–5467 (2000).
Covic, L., Singh, C., Smith, H. & Kuliopulos, A. Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak Syndrome. Thromb. Haemost. 87, 722–727 (2002).
Andrade-Gordon, P. et al. Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. J. Pharm. Exp. Therap. 298, 34–42 (2001).
Ma, L., Hollenberg, M.D. & Wallace, J.L. Thrombin-induced platelet endostatin release is blocked by a proteinase activated receptor-4 (PAR4) antagonist. Br. J. Pharm. 134, 701–704 (2001).
Murray, R. & FitzGerald, G.A. Regulation of thromboxane receptor activation in human platelets. Proc. Natl. Acad. Sci. USA 86, 124–128 (1989).
Woulfe, D., Yang, J. & Brass, L. ADP and platelets: The end of the beginning. J. Clin. Invest. 107, 1503–1504 (2001).
Moroi, M., Jung, S.M., Okuma, M. & Shinmyozu, K. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J. Clin. Invest. 84, 1440–1445 (1989).
Savage, B., Almus-Jacobs, F. & Ruggeri, Z.M. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 94, 657–666 (1998).
Offermanns, S., Toombs, C.F., Hu, Y.-H. & Simon, M.I. Defective platelet activation in Gαq-deficient mice. Nature 389, 183–186 (1997).
Seiler, S.M. et al. Thrombin receptor activation by thrombin and receptor-derived peptides in platelet and CHRF-288 cell membranes: Receptor-stimulated GTPase and evaluation of agonists and partial agonists. Mol. Pharm. 49, 190–197 (1996).
Bernatowicz, M.S. et al. Development of potent thrombin receptor antagonist peptides. J. Med. Chem. 39, 4879–4887 (1996).
Andrade-Gordon, P. et al. Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc. Natl. Acad. Sci. USA 96, 12257–12262 (1999).
Sambrano, G.R., Weiss, E.J., Zheng, Y.W., Huang, W. & Coughlin, S.R. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 413, 74–78 (2001).
Azam, M. et al. Disruption of the mouse μ-calpain gene reveals an essential role in platelet function. Mol. Cell. Biol. 21, 2213–2220 (2001).
Connolly, A.J., Ishihara, H., Kahn, M.L., Farese, R.V. & Coughlin, S.R. Role of the thrombin receptor in development and evidence for a second receptor. Nature 381, 516–519 (1996).
Fabre, J.E. et al. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nature Med. 5, 1199–1202 (1999).
Smyth, S.S., Reis, E.D., Vaananen, J., Zhang, W. & Coller, B.S. Variable protection of β3-integrin-deficient mice from thrombosis initiated by different mechanisms. Blood 15, 1055–1062 (2001).
Hsu-Lin, S., Berman, C.L., Furie, B.C., August, D. & Furie, B. A platelet membrane protein expressed during platelet activation and secretion. J. Biol. Chem. 259, 9121–9126 (1984).
Law, D.A. et al. Integrin cytoplasmic tyrosine motif is required for outside-in αIIbβ3 signalling and platelet function. Nature 401, 808–811 (1999).
Palczewski, K. et al. Crystal structure of rhodopsin: a G protein–coupled receptor. Science 289, 739–745 (2000).
Lambright, D.G. et al. The 2.0 Å crystal structure of a heterotrimeric G protein. Nature 379, 311–319 (1996).
Acknowledgements
Acknowledgments This work was supported by a Natalie V. Zucker Award (to L.C.) and National Institutes of Health grants R01HL64701, R01HL57905 (to A.K.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Tufts-New England Medical Center Hospital has submitted a patent application covering pepducins.
Rights and permissions
About this article
Cite this article
Covic, L., Misra, M., Badar, J. et al. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med 8, 1161–1165 (2002). https://doi.org/10.1038/nm760
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm760
This article is cited by
-
Therapeutic strategies for thrombosis: new targets and approaches
Nature Reviews Drug Discovery (2020)
-
Dysregulated protease activated receptor 1 (PAR1) promotes metastatic phenotype in breast cancer through HMGA2
Oncogene (2016)
-
Intranasal and Intramuscular Administration of Lysine-Palmitoylated Peptide 612–627 of Thyroid-Stimulating Hormone Receptor Increases the Level of Thyroid Hormones in Rats
International Journal of Peptide Research and Therapeutics (2015)
-
Regulation of the Melanocortin-Sensitive Adenylate Cyclase System by N-Acylated Peptide 71-82 of Type 4 Melanocortin Receptor
Bulletin of Experimental Biology and Medicine (2015)